What Is Hexapeptide-11? Definition and What Research Reports

Definition

Hexapeptide-11 is the International Nomenclature of Cosmetic Ingredients (INCI) name for a short peptide composed of six amino acids that appears in topical cosmetic formulations and in laboratory studies of skin-cell biology. In the peer-reviewed literature it has been described as a yeast fermentate–derived peptide and investigated in cultured human diploid fibroblasts, where the study characterised it as a modulator of the proteostasis network (PMID 25974626). It is a cosmetic ingredient designation rather than the name of an approved drug, and the studies summarised on this page were conducted in cell culture, not in patients.

Where the Name Comes From

The name is purely descriptive and administrative. The prefix hexa- indicates six amino acid residues; peptide indicates a chain shorter than a protein; and the numeral 11 is a registry index assigned under cosmetic ingredient nomenclature. That numeral carries no biological meaning. Hexapeptide-11 is not structurally or functionally related to other numbered hexapeptides — such as the acetyl- or palmitoyl-modified hexapeptides found in other cosmetic formulations — simply because the numbers sit near one another in a list. Readers comparing ingredient labels cannot infer shared sequence, shared origin or shared behaviour from the numbering alone.

Regarding origin, the 2015 Redox Biology report examined hexapeptide-11 as a fermentation-derived peptide applied to human diploid fibroblast cultures (PMID 25974626). This places it among cosmetic peptides obtained by biotechnological production rather than by extraction from animal tissue or by long chemical synthesis routes.

How the Term Is Used in Peptide Research

In the research literature, "hexapeptide-11" is used in three fairly distinct contexts:

• As an ingredient label. Cosmetic chemistry papers and formulation reviews use the INCI name when listing peptide actives in a topical product or test article.
• As a test compound in cell culture. Skin-biology papers apply the peptide to cultured fibroblasts or dermal papilla cells and measure markers of stress response, senescence or protein turnover.
• As a member of a peptide class. Reviews of cosmeceutical actives group short peptides together by presumed mechanism — signalling, carrier, neurotransmitter-modulating or enzyme-modulating — and hexapeptide-11 is generally discussed with peptides studied for effects on cellular stress and ageing pathways.

Importantly, the term describes a defined ingredient, not a therapeutic category. Nothing in the nomenclature implies that a compound has been tested in humans for any indication.

What the Published Literature Reports

The most specific published work is a 2015 study in Redox Biology, in which researchers described hexapeptide-11 as a novel modulator of the proteostasis network in human diploid fibroblasts — the interconnected systems, including proteasomal and lysosomal degradation pathways, that control protein quality and turnover inside cells (PMID 25974626). That work was performed in cultured human cells, and the reported outcomes were cellular and biochemical rather than clinical.

Two further in vitro papers place hexapeptide-type cosmetic peptides in the broader context of skin-cell senescence research. A 2013 study in the Journal of Cosmetic Science examined the modulation of cellular senescence in fibroblasts and dermal papilla cells in vitro, testing cosmetic peptide ingredients against markers of the senescent phenotype (PMID 23578831). A 2021 study in Skin Pharmacology and Physiology evaluated five cosmeceutical peptide mixtures in a hydrogen peroxide–induced model of premature senescence in human skin fibroblasts, and the authors reported protective and anti-ageing effects in that culture system (PMID 33849044). Both models use oxidative or replicative stress in cultured cells as a stand-in for ageing processes; neither is a human trial, and neither establishes what a finished topical product does on intact skin.

Summary of the cited studies

Formulation and Delivery Context

Discussion of any topical peptide inevitably involves the question of whether the molecule reaches the cells studied in a dish. A 2022 paper in the Journal of Cosmetic Dermatology on topical hyaluronic acid technology examined how molecular size shapes the behaviour of a topically applied ingredient, and the authors argued that size is a determining variable in topical technology design (PMID 35486441). The same principle — that in vitro activity does not automatically translate through the stratum corneum — is the standard caveat applied to cosmetic peptides.

Separately, a 2022 review in the Journal of Drugs in Dermatology described pigmentation management as a multipronged approach combining topical agents, procedures and photoprotection rather than reliance on any single active (PMID 36342738). That framing is useful context for how dermatology literature treats individual cosmetic ingredients: as one component among several, evaluated within a formulation and a broader regimen.

Safety and Tolerability: What Studies Report

The verified literature summarised here consists of cell-culture experiments and formulation reviews; none of the cited papers were designed as human safety trials of hexapeptide-11, and none reported adverse-event rates, tolerability data or systemic exposure in people. The 2015 fibroblast work reported cellular outcomes in culture rather than clinical safety endpoints (PMID 25974626), and the 2021 senescence study likewise reported outcomes in human skin fibroblast cultures rather than in volunteers (PMID 33849044). Absence of reported adverse events in in vitro work is not evidence of safety in humans; it simply reflects what those experimental designs could measure. This page is for educational purposes only and is not medical advice; consult a licensed physician or qualified clinician about any skincare or health question.

Limits of the Evidence

1. Mostly in vitro. The cited studies used cultured human fibroblasts and dermal papilla cells; cell-culture findings do not predict outcomes on living skin.
2. Mixtures versus single ingredients. The 2021 work tested peptide mixtures rather than isolated single peptides, which limits attribution of any reported effect to one component (PMID 33849044).
3. Mechanism-level endpoints. Proteostasis and senescence markers are biological readouts, not visible cosmetic outcomes; the 2015 study reported the former (PMID 25974626).
4. No dose framework. The verified literature cited here does not support any statement about amounts, concentrations or duration of use in humans, so none is given.

Related Terms

• INCI name — the standardised cosmetic ingredient label under which hexapeptide-11 appears on product listings.
• Proteostasis network — the cellular machinery for protein synthesis, folding and degradation, the system examined in the 2015 fibroblast study (PMID 25974626).
• Cellular senescence — a state of stable growth arrest used as an in vitro ageing endpoint in fibroblast and dermal papilla research (PMID 23578831).
• Cosmeceutical peptide — an umbrella term for short peptides included in topical formulations and studied for skin-related endpoints.

References

• Hexapeptide-11 is a novel modulator of the proteostasis network in human diploid fibroblasts (Redox Biology, 2015)
• Protective and Anti-Aging Effects of 5 Cosmeceutical Peptide Mixtures on Hydrogen Peroxide-Induced Premature Senescence in Human Skin Fibroblasts (Skin Pharmacology and Physiology, 2021)
• Modulation of cellular senescence in fibroblasts and dermal papillae cells in vitro (Journal of Cosmetic Science, 2013)
• Designing topical hyaluronic acid technology-Size does matter… (Journal of Cosmetic Dermatology, 2022)
• Advances in Pigmentation Management: A Multipronged Approach (Journal of Drugs in Dermatology, 2022)